Abstract: The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. The object of the invention was to create an efficient and safe universal antitumor agent, the production of which effective, quick and easy. This problem is solved by the proposed humanized monoclonal antibody specific to syndecan-1, of the IgG4 isotype, or with IgG3 fragments and amino acid substitutions for the increase the antibody half-life, characterized by a definite combination of the calculated and created by the authors amino acid and nucleotide sequences, which is used as a self-acting substance for the therapy of tumor diseases. Nucleotide sequences additionally contain a fragment coding for a signal secretory sequence at the N-terminus, and are codon-optimized to increase antibody production in mammalian cells.

Abstract: The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. The object of the invention was to create an efficient and safe universal antitumor agent, the production of which effective, quick and easy. This problem is solved by the proposed humanized monoclonal antibody specific to syndecan-1, of the IgG4 isotype, or with IgG3 fragments and amino acid substitutions for the increase the antibody half-life, characterized by a definite combination of the calculated and created by the authors amino acid and nucleotide sequences, which is used as a self-acting substance for the therapy of tumor diseases. Nucleotide sequences additionally contain a fragment coding for a signal secretory sequence at the N-terminus, and are codon-optimized to increase antibody production in mammalian cells.

Abstract: The invention (embodiments) relates to the field of medicine, pharmacology, biotechnology, molecular biology, genetic engineering and can be used for analgesia. A plasmid DNA is given for transient expression in mammalian cells, represented by a skeleton that contains prokaryotic and eukaryotic elements and a polynucleotide encoding human alpha defensin HNP-1 or HNP-2 or HNP-3 (embodiments). A producer of such plasmid DNA is also given based on a bacterial cell (embodiments) and an analgesic agent for use in mammals, in particular, human, based on it (embodiments). The technical result from the use of embodiments of the invention is expressed in expanding the range of analgesic products, in an increase of the duration of analgesia, in an increase of the safety of analgesia, in simplification and cheapening of the production of the analgesic.

Abstract: A vaccine having a fusion protein set forth as SEQ ID NO:1 containing antigenic determinants of haemagglutinins of influenza A and B viruses and flagellin fragments functioning as safe adjuvant, joined via flexible hinges is given, which can be used for prophylaxis of influenza caused by existing influenza A and B strains as well as by possible reassortants. Usage of the vaccine will provide a universal protection against influenza and provides safety, efficacy, polyvalence and preventive effect.

Abstract: A vaccine comprising a chimeric protein set forth as SEQ ID NO: 1 containing immunogenic epitopes of conservative Streptococcus pneumoniae proteins PspA, Spr1895, PsaA, as well as flagellin components, connected via flexible links, wherein the flagellin components function as adjuvant.

Abstract: The problem to be solved: absence of safe efficient universal vaccine against influenza. The solution: The vaccine based on the fusion protein consisting of antigenic determinants of haemagglutinins of influenza A and B viruses and flagellin fragments functioning as safe adjuvant (SEQ ID NO:1) joined via flexible hinges is given which can be used for prophylaxis of influenza caused by existing influenza A and B strains as well as by possible reassortants. Safety, efficacy, polyvalence and preventive effect have been demonstrated. Usage of the present vaccine will allow to provide a universal protection against influenza.

Abstract: A vaccine based on the chimeric protein consisting of immunogenic epitopes of conservative Streptococcus pneumoniae proteins: PspA, Spr1895, and PsaA, as well as flagellin components (FliC1, FliC2) functioning as safe adjuvant, the proteins or the peptides homologs to those to not less than 60% of their amino acid sequence, connected via flexible links.